Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved

Detalles Bibliográficos
Autores principales: Yoneda, Masato, Kobayashi, Takashi, Wada, Naohiro, Otani, Tomohiro, Nogami, Asako, Iwaki, Michihiro, Nakajima, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598311/
https://www.ncbi.nlm.nih.gov/pubmed/37886193
http://dx.doi.org/10.21037/hbsn-23-342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598311/
https://www.ncbi.nlm.nih.gov/pubmed/37886193
http://dx.doi.org/10.21037/hbsn-23-342

Ejemplares similares